229 related articles for article (PubMed ID: 32820040)
41. HMOX1 regulates ferroptosis via mic14 and its impact on chemotherapy resistance in small-cell lung cancer.
Sun Y; Zhang J
Anticancer Drugs; 2024 Jun; 35(5):397-411. PubMed ID: 38527419
[TBL] [Abstract][Full Text] [Related]
42. Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.
Fielitz K; Althoff K; De Preter K; Nonnekens J; Ohli J; Elges S; Hartmann W; Klöppel G; Knösel T; Schulte M; Klein-Hitpass L; Beisser D; Reis H; Eyking A; Cario E; Schulte JH; Schramm A; Schüller U
Oncotarget; 2016 Nov; 7(46):74415-74426. PubMed ID: 27769070
[TBL] [Abstract][Full Text] [Related]
43. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma.
Tavana O; Li D; Dai C; Lopez G; Banerjee D; Kon N; Chen C; Califano A; Yamashiro DJ; Sun H; Gu W
Nat Med; 2016 Oct; 22(10):1180-1186. PubMed ID: 27618649
[TBL] [Abstract][Full Text] [Related]
44. Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
Ito T; Matsubara D; Tanaka I; Makiya K; Tanei ZI; Kumagai Y; Shiu SJ; Nakaoka HJ; Ishikawa S; Isagawa T; Morikawa T; Shinozaki-Ushiku A; Goto Y; Nakano T; Tsuchiya T; Tsubochi H; Komura D; Aburatani H; Dobashi Y; Nakajima J; Endo S; Fukayama M; Sekido Y; Niki T; Murakami Y
Cancer Sci; 2016 Oct; 107(10):1527-1538. PubMed ID: 27418196
[TBL] [Abstract][Full Text] [Related]
45. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance.
Chen H; Zhu X; Sun R; Ma P; Zhang E; Wang Z; Fan Y; Zhou G; Mao R
Invest New Drugs; 2020 Dec; 38(6):1707-1716. PubMed ID: 32468271
[TBL] [Abstract][Full Text] [Related]
46. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.
Dammert MA; Brägelmann J; Olsen RR; Böhm S; Monhasery N; Whitney CP; Chalishazar MD; Tumbrink HL; Guthrie MR; Klein S; Ireland AS; Ryan J; Schmitt A; Marx A; Ozretić L; Castiglione R; Lorenz C; Jachimowicz RD; Wolf E; Thomas RK; Poirier JT; Büttner R; Sen T; Byers LA; Reinhardt HC; Letai A; Oliver TG; Sos ML
Nat Commun; 2019 Aug; 10(1):3485. PubMed ID: 31375684
[TBL] [Abstract][Full Text] [Related]
47. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract][Full Text] [Related]
48. Overexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494.
Bai Y; Sun Y; Peng J; Liao H; Gao H; Guo Y; Guo L
Oncotarget; 2014 Sep; 5(17):7760-75. PubMed ID: 25226615
[TBL] [Abstract][Full Text] [Related]
49. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of MYCN promotes proliferation of non-small cell lung cancer.
Liu K; Wang S; Liu Y; Gu J; Gu S; Xu Z; Zhang R; Wang Z; Ma H; Chen Y; Ji L
Tumour Biol; 2016 Sep; 37(9):12855-12866. PubMed ID: 27449038
[TBL] [Abstract][Full Text] [Related]
51. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
Sarvi S; Mackinnon AC; Avlonitis N; Bradley M; Rintoul RC; Rassl DM; Wang W; Forbes SJ; Gregory CD; Sethi T
Cancer Res; 2014 Mar; 74(5):1554-65. PubMed ID: 24436149
[TBL] [Abstract][Full Text] [Related]
52. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer.
Ranade AR; Cherba D; Sridhar S; Richardson P; Webb C; Paripati A; Bowles B; Weiss GJ
J Thorac Oncol; 2010 Aug; 5(8):1273-8. PubMed ID: 20548249
[TBL] [Abstract][Full Text] [Related]
54. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer.
Ran X; Wu BX; Shi M; Song L; Nixon K; Philip V; He HH; Tsao MS; Lok BH
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1308-1314. PubMed ID: 38104868
[TBL] [Abstract][Full Text] [Related]
55. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer.
Kohmo S; Kijima T; Otani Y; Mori M; Minami T; Takahashi R; Nagatomo I; Takeda Y; Kida H; Goya S; Yoshida M; Kumagai T; Tachibana I; Yokota S; Kawase I
Cancer Res; 2010 Oct; 70(20):8025-35. PubMed ID: 20940407
[TBL] [Abstract][Full Text] [Related]
56. [Role of SPHK1 regulates multi-drug resistance of small cell lung cancer
and its clinical significance].
Yang L; Hu H; Deng Y; Bai Y
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):769-77. PubMed ID: 25404266
[TBL] [Abstract][Full Text] [Related]
57. USP7 facilitates SMAD3 autoregulation to repress cancer progression in p53-deficient lung cancer.
Huang YT; Cheng AC; Tang HC; Huang GC; Cai L; Lin TH; Wu KJ; Tseng PH; Wang GG; Chen WY
Cell Death Dis; 2021 Sep; 12(10):880. PubMed ID: 34580281
[TBL] [Abstract][Full Text] [Related]
58. Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation.
Liang S; Wang Q; Wen Y; Wang Y; Li M; Wang Q; Peng J; Guo L
Cancer Sci; 2023 Mar; 114(3):921-936. PubMed ID: 36377249
[TBL] [Abstract][Full Text] [Related]
59. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
60. Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A.
Pan B; Chen Y; Song H; Xu Y; Wang R; Chen L
Oncotarget; 2015 Jan; 6(1):317-31. PubMed ID: 25426560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
